Literature DB >> 18402545

Familial hypercholesterolemia: current treatment and advances in management.

Roeland Huijgen1, Maud N Vissers, Joep C Defesche, Peter J Lansberg, John J P Kastelein, Barbara A Hutten.   

Abstract

Heterozygous familial hypercholesterolemia is associated with elevated levels of LDL-cholesterol and the development of premature cardiovascular disease. The condition is considerably under-diagnosed and under-treated. Statins are the first choice treatment for all patients with heterozygous familial hypercholesterolemia. For those patients who do not reach their treatment target or who are unable to use adequate statin dose, several alternative treatment modalities can be used, either as add-on therapy or as monotherapy. In this review the various treatment options are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18402545     DOI: 10.1586/14779072.6.4.567

Source DB:  PubMed          Journal:  Expert Rev Cardiovasc Ther        ISSN: 1477-9072


  28 in total

1.  Autosomal recessive hypercholesterolaemia in a Morrocan family due to a mutation of the G266C LDL receptor.

Authors:  Siham El Aziz; Asma Chadli; Hassan El Ghomari; Ahmed Farouqi
Journal:  BMJ Case Rep       Date:  2012-05-23

2.  Improved access to life insurance after genetic diagnosis of familial hypercholesterolaemia: cross-sectional postal questionnaire study.

Authors:  Roeland Huijgen; Sietske J M Homsma; Barbara A Hutten; Iris Kindt; Maud N Vissers; John J P Kastelein; Jan L A van Rijckevorsel
Journal:  Eur J Hum Genet       Date:  2012-02-01       Impact factor: 4.246

3.  SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia.

Authors:  Paulo Caleb Junior Lima Santos; Ana Carolina Moron Gagliardi; Márcio Hiroshi Miname; Ana Paula Chacra; Raul Dias Santos; Jose Eduardo Krieger; Alexandre Costa Pereira
Journal:  Eur J Clin Pharmacol       Date:  2011-09-18       Impact factor: 2.953

4.  Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia.

Authors:  R Huijgen; S W Fouchier; M Denoun; B A Hutten; M N Vissers; G Lambert; J J P Kastelein
Journal:  J Lipid Res       Date:  2012-02-27       Impact factor: 5.922

5.  New Treatments on the Horizon for Familial Hypercholesterolemia.

Authors:  Khalid Al-Rasadi; Khalid Al-Waili
Journal:  Oman Med J       Date:  2017-11

6.  Migratory polyarthritis in familial hypercholesterolemia (type IIa hyperlipoproteinemia).

Authors:  Partha Pratim Chakraborty; Sagnik Mukhopadhyay; Arun Achar; Mallika Pal; Prabodh Chandra Mondal
Journal:  Indian J Pediatr       Date:  2010-02-08       Impact factor: 1.967

7.  Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal.

Authors:  Roeland Huijgen; Iris Kindt; Sjoerd B J Verhoeven; Eric J G Sijbrands; Maud N Vissers; John J P Kastelein; Barbara A Hutten
Journal:  PLoS One       Date:  2010-02-15       Impact factor: 3.240

8.  Hypercholesterolemia and microvascular dysfunction: interventional strategies.

Authors:  Phoebe A Stapleton; Adam G Goodwill; Milinda E James; Robert W Brock; Jefferson C Frisbee
Journal:  J Inflamm (Lond)       Date:  2010-11-18       Impact factor: 4.981

Review 9.  Optimal management of familial hypercholesterolemia: treatment and management strategies.

Authors:  Mohammad Hassan Nemati; Behrooz Astaneh
Journal:  Vasc Health Risk Manag       Date:  2010-12-03

10.  Adeno-associated virus serotype 8 gene therapy leads to significant lowering of plasma cholesterol levels in humanized mouse models of homozygous and heterozygous familial hypercholesterolemia.

Authors:  Sadik H Kassim; Hui Li; Peter Bell; Suryanarayan Somanathan; William Lagor; Frank Jacobs; Jeffrey Billheimer; James M Wilson; Daniel J Rader
Journal:  Hum Gene Ther       Date:  2012-11-14       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.